In this report, the Commission provides biokinetic and dosimetric models for 33 radiopharmaceuticals, as well as recommendations related to breast feeding for mothers who have undergone a nuclear medicine investigation. The report is based on Addenda 3-9 to Publication 53. Addenda 3-7 have been available on the ICRP website (www.icrp.org) as interim reports. The work has been carried out by a Joint Task Group of ICRP Committees 2 and 3. This publication provides biokinetic models, absorbed doses, and effective doses for the following radiopharmaceuticals: C-11-acetate; C-11-amino acids; C-11-brain receptor substances; C-11-methionine; F-18-amino acids; F-18-FET; F-18-FDG; In-111-monoclonal antibodies/fragments; I-123-fatty acids (BMIPP, IPPA); I-123-monoclonal antibodies/fragments; I-131-monoclonal antibodies/fragments; and Tl-201-ion. The publication also provides realistic maximum models for C-11 and F-18 substances, for which no specific models are available.
PREFACE INTRODUCTION SELECTION OF RADIOPHARMACEUTICALS SELECTION OF ORGANS AND TISSUES FOR DOSE CALCULATIONS BIOKINETIC MODELS AND DATA METHODS FOR CALCULATING ABSORBED DOSE EFFECTIVE DOSE DOSE TO EMBRYO AND FETUS REFERENCES, MAIN TEXT ANNEX A. SPECIAL BIOKINETIC AND DOSIMETRIC MODELS ANNEX B. EXPLANATIONS ANNEX C. BIOKINETIC MODELS AND DOSE TABLES ANNEX D. RECOMMENDATIONS ON BREAST-FEEDING INTERRUPTIONS ANNEX E. RADIATION EXPOSURE OF HANDS IN RADIOPHARMACIES; MONITORING OF THE DOSES AND OPTIMISATION OF PROTECTION